ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022

07 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments

23 May 2022 08:00:01 By Nasdaq GlobeNewswire

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial

23 May 2022 08:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports First Quarter 2022 Financial Results

11 May 2022 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference

09 May 2022 08:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11

04 May 2022 16:05:02 By Nasdaq GlobeNewswire

Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May

01 May 2022 07:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering

24 Mar 2022 22:41:11 By Nasdaq GlobeNewswire

Ascendis Pharma Announces Proposed Convertible Senior Notes Offering

23 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

13 Mar 2022 17:53:47 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update

02 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2

25 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

13 Jan 2022 08:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference

10 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline

14 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14

07 Dec 2021 17:41:04 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism

18 Nov 2021 16:42:05 By Nasdaq GlobeNewswire

Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference

17 Nov 2021 16:05:00 By Nasdaq GlobeNewswire